Validation and Forced Degradation Studies for the Determination of Erlotinib in Bulk and Pharmaceutical Dosage Forms by RP-HPLC

Authors

  • K. Kalyani Department of Chemistry, R.V.R & J.C College of Engineering, Guntur, Andhra Pradesh, India
  • V. Anuradha Vignan’s Nirula Institute of Technology and Science, Guntur, Andhra Pradesh, India
  • Rlc. Sasidhar Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India
  • S. Vidyadhara Chebrolu Hanumaiah Institute of Pharmaceutical Sciences, Guntur, Andhra Pradesh, India

DOI:

https://doi.org/10.37591/rrjodfdp.v3i2.342

Abstract

A new reverse phase-high performance liquid chromatography (RP-HPLC) have been developed and validated for the determination of Erlotinib in bulk drug and pharmaceutical dosage form. The developed method is rapid, accurate, precise, simple and economical. The separation was carried out using column Hypersil ODS C-18 (150 mm x 4.6 mm 5 μm particle size) in isocratic mode, using mobile phase composition of 0.1% orthophosphoric acid: Acetonitrile in the ratio of 20:80 and PH adjusted to 4.0±0.1 with 1 M sodium hydroxide. The flow rate was 1.0 ml/min effluents are monitored at 245 nm. Chromatogram showed peak at a retention time of 2.706 min for Erlotinib. The method is validated according to ICH guidelines system suitability, linearity, precision, accuracy, specificity, ruggedness, robustness, LOD and LOQ. The calibration plot showed good linear relationship with r2 = 0.999 in the concentration range of 25-150 μg/ml for Erlotinib. The LOD and LOQ were found to be 1.07 μg/ml and 3.24 μg/ml. Accuracy was found to be 99.89%. Erlotinib was also exposed to acidic, alkaline, oxidative, thermal and photolytic conditions and the stressed samples were analyzed by the proposed method. Degradation studies showed that the Erlotinib was highly stable under acidic, alkaline, oxidative, thermal and photolytic conditions without change in RT values compared to standard and no significant degraded peaks were observed. The high percentage of stability under stress conditions confirms the suitability of the method for the determination of Erlotinib in pure and marketed formulations.

 

Keywords: Erlotinib, RP-HPLC, validation, Forced degradation studies, ICH guidelines

Cite this Article

K. Kalyani, V. Anuradha, Rlc. Sasidhar et al. Validation and Forced Degradation Studies for the Determination of Erlotinib in Bulk and Pharmaceutical Dosage Forms by RP-HPLC. Research & Reviews: A Journal of Drug Formulation, Development and Production. 2016; 3(2): 44–53p

Downloads

Published

2019-02-27

Issue

Vol. 3 No. 2 (2016)

Section

Review Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.